New York State Common Retirement Fund Boosts Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)

New York State Common Retirement Fund grew its stake in Acelyrin, Inc. (NASDAQ:SLRN) by 84.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,181 shares of the company’s stock after acquiring an additional 6,032 shares during the quarter. New York State Common Retirement Fund’s holdings in Acelyrin were worth $98,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of SLRN. Amalgamated Bank purchased a new position in Acelyrin in the 3rd quarter worth approximately $44,000. Strs Ohio bought a new position in shares of Acelyrin during the third quarter valued at $71,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Acelyrin by 608.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,716 shares of the company’s stock valued at $80,000 after buying an additional 9,203 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Acelyrin in the 4th quarter worth about $84,000. Finally, TD Asset Management Inc raised its position in Acelyrin by 22.0% in the 3rd quarter. TD Asset Management Inc now owns 75,164 shares of the company’s stock worth $764,000 after buying an additional 13,554 shares during the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Acelyrin in a report on Wednesday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Acelyrin presently has a consensus rating of “Moderate Buy” and an average target price of $21.67.

Acelyrin Price Performance

SLRN stock opened at $4.39 on Friday. Acelyrin, Inc. has a 12 month low of $4.14 and a 12 month high of $29.88. The firm’s 50-day moving average is $5.79 and its 200 day moving average is $7.03. The company has a market capitalization of $434.74 million and a PE ratio of -1.84.

Acelyrin (NASDAQ:SLRN) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.25. Sell-side analysts forecast that Acelyrin, Inc. will post -4.17 EPS for the current fiscal year.

Insiders Place Their Bets

In other Acelyrin news, CEO Shao-Lee Lin sold 15,701 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the completion of the sale, the chief executive officer now directly owns 1,587,335 shares in the company, valued at $12,063,746. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.60% of the stock is currently owned by corporate insiders.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.